Drug intelligence / Profile preview

NOSHIN SHAHD

Development stage: Phase 4
Lead developer: Kerman University of Medical Sciences
Modality: Small Molecules
Administration: Oral

Overview

NOSHIN SHAHD is a traditional herbal medicinal product investigated by Kerman Medical University for the management of type 2 diabetes mellitus. Administered as an oral syrup, it is being evaluated in clinical settings for its ability to improve glycemic control, specifically by reducing HOMA-estimated insulin resistance. The formulation is also studied for its impact on inflammatory biomarkers and oxidative stress parameters. It has been assigned a registration number (12/14484) by the Iran Food and Drug Administration (IFDA) and is typically administered at a dosage of 20 ml three times daily following meals.

Brand names: NOSHIN SHAHD
Other names: anti-diabetic herbal drugtraditional anti-diabetic herbal drug

Beyond the preview

Go deeper on NOSHIN SHAHD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOSHIN SHAHD.

Explore the full profile